---
title: "Funding allows CroíValve to advance US early feasibility study of Duo tricuspid valve"
date: "2024-08-08T09:36:14.000Z"
publishedDate: "8 août 2024"
summary: "CroíValve has closed a US$16 million Series B financing round. Proceeds from the financing will be used to fund the TANDEM II early feasibility study, a US Food and Drug Administration (FDA)-approved, prospective, multicentre study to evaluate the safety and performance of the Duo system in patients with severe or greater symptomatic tricuspid regurgitation (TR)."
importance: ""
sourceUrl: "https://cardiovascularnews.com/croivalve-series-b-financing/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2024-08-08-funding-allows-croivalve-to-advance-us-early-feasibility-study-of-duo-tricuspid-valve"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/08/DUO_System_Inside_Heart_Imge_edited.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/croivalve-series-b-financing/"
---

![Funding allows CroíValve to advance US early feasibility study of Duo tricuspid valve](https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/08/DUO_System_Inside_Heart_Imge_edited.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/croivalve-series-b-financing/*

## L’essentiel

CroíValve has closed a US$16 million Series B financing round. Proceeds from the financing will be used to fund the TANDEM II early feasibility study, a US Food and Drug Administration (FDA)-approved, prospective, multicentre study to evaluate the safety and performance of the Duo system in patients with severe or greater symptomatic tricuspid regurgitation (TR).

## Lien source

https://cardiovascularnews.com/croivalve-series-b-financing/
